One hundred and twenty-seven patients (45.4%) had hormone receptor positive/HER2 negative breast cancer, 41 patients (14.6%) had hormone receptor positive/HER2 positive breast cancer, 40 patients (14.3%) had hormone receptor negative/HER2 positive breast cancer and 72 patients (25.7%) had triple negative breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.